| Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact | Frank Vinluan | 06/01/20 | New York |
| AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics | Frank Vinluan | 03/25/20 | Europe |
| Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B | Frank Vinluan | 11/25/19 | New York |
| Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More | Frank Vinluan | 11/22/19 | National |
| Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug | Frank Vinluan | 10/31/19 | Boston |
| MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms | Ben Fidler | 05/20/19 | New York |
| Exosomes Head to Wall Street As Codiak Biosciences Lines Up IPO | Ben Fidler | 04/30/19 | Boston |
| Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More | Ben Fidler | 04/19/19 | National |
| Alnylam Makes Case For 2nd RNAi Drug at Big Liver Disease Meeting | Ben Fidler | 04/12/19 | Boston |
| Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases | Ben Fidler | 04/08/19 | Boston |
| Data in Hand, Alnylam to Seek OK for Second RNAi Drug | Ben Fidler | 03/06/19 | Boston |
| 15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) | Ben Fidler | 12/18/18 | National |
| Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel | Ben Fidler | 11/09/18 | National |
| Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M | Ben Fidler | 10/29/18 | Boston |
| Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug | Ben Fidler | 10/15/18 | Boston |
| Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More | Frank Vinluan | 10/05/18 | National |
| Janssen Reaches $250M Deal for Rights to Arrowhead’s Hep B RNAi Drug | Jeff Buchanan | 10/04/18 | Wisconsin |
| With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug | Ben Fidler | 09/27/18 | Boston |
| Arrowhead Shares Pop on Early Clinical Data for Hepatitis B Drug | Jeff Buchanan | 09/06/18 | Wisconsin |
| Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug | Ben Fidler | 08/10/18 | Boston |
| Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More | Ben Fidler | 08/10/18 | National |
| Bio Roundup: Alnylam’s Moment, Read on Rebates, Skinny Plans & More | Alex Lash | 08/03/18 | National |
| Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision | Ben Fidler | 08/03/18 | Boston |
| CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot” | Ben Fidler | 05/23/18 | Boston |
| An Inside Look at CAR-T, Gene Therapy Launches at ‘What’s Hot’ May 16 | Ben Fidler | 05/09/18 | Boston |
| Paying for Gene Therapy, CRISPR in People, RNAi at “What’s Hot” on May 16 | Ben Fidler | 03/05/18 | Boston |
| LGC Acquires Lucigen, Marking Latest Exit for CEO Ralph Kauten | Jeff Buchanan | 02/16/18 | Wisconsin |
| Arrowhead Plans Return to Clinic With New Study of Hep B Drug | Jeff Buchanan | 02/16/18 | Wisconsin |
| Notes From the JPM ’18 Vortex: Gene Therapy’s Reckoning and Lonely Cabs | Ben Fidler | 01/11/18 | National |
| In Week of Hemophilia News, Alnylam Drug Cleared to Move Forward | Ben Fidler | 12/15/17 | Boston |
